annual EBITDA:
-$110.33M-$28.43M(-34.71%)Summary
- As of today (July 6, 2025), URGN annual EBITDA is -$110.33 million, with the most recent change of -$28.43 million (-34.71%) on December 31, 2024.
- During the last 3 years, URGN annual EBITDA has fallen by -$2.74 million (-2.54%).
- URGN annual EBITDA is now -11013.45% below its all-time high of $1.01 million, reached on December 31, 2016.
Performance
URGN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$38.89M-$8.22M(-26.81%)Summary
- As of today (July 6, 2025), URGN quarterly EBITDA is -$38.89 million, with the most recent change of -$8.22 million (-26.81%) on March 31, 2025.
- Over the past year, URGN quarterly EBITDA has dropped by -$9.45 million (-32.11%).
- URGN quarterly EBITDA is now -378.11% below its all-time high of $13.98 million, reached on December 31, 2016.
Performance
URGN quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$119.79M-$9.45M(-8.57%)Summary
- As of today (July 6, 2025), URGN TTM EBITDA is -$119.79 million, with the most recent change of -$9.45 million (-8.57%) on March 31, 2025.
- Over the past year, URGN TTM EBITDA has dropped by -$34.65 million (-40.70%).
- URGN TTM EBITDA is now -2720.01% below its all-time high of $4.57 million, reached on December 31, 2016.
Performance
URGN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
URGN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -34.7% | -32.1% | -40.7% |
| 3 y3 years | -2.5% | -42.3% | -9.5% |
| 5 y5 years | -2.0% | -2.0% | +9.3% |
URGN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -34.7% | at low | -120.2% | at low | -46.3% | at low |
| 5 y | 5-year | -34.7% | +11.5% | -120.2% | at low | -46.3% | +12.9% |
| alltime | all time | <-9999.0% | +11.5% | -378.1% | +1.4% | -2720.0% | +12.9% |
URGN EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$38.89M(+26.8%) | -$119.79M(+8.6%) |
| Dec 2024 | -$110.33M(+34.7%) | -$30.66M(+48.9%) | -$110.33M(+12.8%) |
| Sep 2024 | - | -$20.59M(-30.5%) | -$97.82M(+3.1%) |
| Jun 2024 | - | -$29.64M(+0.7%) | -$94.89M(+11.5%) |
| Mar 2024 | - | -$29.43M(+62.2%) | -$85.13M(+3.9%) |
| Dec 2023 | -$81.90M(-16.2%) | -$18.15M(+2.8%) | -$81.90M(-7.2%) |
| Sep 2023 | - | -$17.66M(-11.2%) | -$88.26M(-4.7%) |
| Jun 2023 | - | -$19.89M(-24.1%) | -$92.59M(-4.2%) |
| Mar 2023 | - | -$26.20M(+6.9%) | -$96.65M(-1.2%) |
| Dec 2022 | -$97.77M(-9.1%) | -$24.51M(+11.4%) | -$97.77M(-2.4%) |
| Sep 2022 | - | -$21.99M(-8.1%) | -$100.13M(-7.2%) |
| Jun 2022 | - | -$23.94M(-12.4%) | -$107.90M(-1.4%) |
| Mar 2022 | - | -$27.33M(+1.7%) | -$109.42M(+1.5%) |
| Dec 2021 | -$107.60M(-13.7%) | -$26.86M(-9.7%) | -$107.78M(+0.2%) |
| Sep 2021 | - | -$29.76M(+16.8%) | -$107.55M(+1.1%) |
| Jun 2021 | - | -$25.47M(-0.8%) | -$106.42M(-5.2%) |
| Mar 2021 | - | -$25.69M(-3.6%) | -$112.28M(-10.0%) |
| Dec 2020 | -$124.69M | -$26.64M(-6.9%) | -$124.69M(-9.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$28.63M(-8.6%) | -$137.50M(+4.2%) |
| Jun 2020 | - | -$31.32M(-17.8%) | -$132.01M(+6.3%) |
| Mar 2020 | - | -$38.10M(-3.4%) | -$124.13M(+14.8%) |
| Dec 2019 | -$108.15M(+40.9%) | -$39.44M(+70.4%) | -$108.15M(+16.7%) |
| Sep 2019 | - | -$23.14M(-1.3%) | -$92.66M(+2.3%) |
| Jun 2019 | - | -$23.45M(+6.0%) | -$90.55M(+5.9%) |
| Mar 2019 | - | -$22.13M(-7.6%) | -$85.49M(+11.4%) |
| Dec 2018 | -$76.76M(+288.8%) | -$23.95M(+13.9%) | -$76.76M(+22.0%) |
| Sep 2018 | - | -$21.03M(+14.4%) | -$62.91M(+49.2%) |
| Jun 2018 | - | -$18.38M(+37.2%) | -$42.17M(+42.2%) |
| Mar 2018 | - | -$13.40M(+32.7%) | -$29.65M(+50.2%) |
| Dec 2017 | -$19.74M(-2052.8%) | -$10.10M(+3431.5%) | -$19.74M(-555.0%) |
| Sep 2017 | - | -$286.00K(-95.1%) | $4.34M(-403.9%) |
| Jun 2017 | - | -$5.86M(+67.9%) | -$1.43M(-232.3%) |
| Mar 2017 | - | -$3.49M(-125.0%) | $1.08M(-76.4%) |
| Dec 2016 | $1.01M(-108.2%) | $13.98M(-331.0%) | $4.57M(-148.6%) |
| Sep 2016 | - | -$6.05M(+80.3%) | -$9.41M(+180.3%) |
| Jun 2016 | - | -$3.36M | -$3.36M |
| Dec 2015 | -$12.30M | - | - |
FAQ
- What is UroGen Pharma annual EBITDA?
- What is the all time high annual EBITDA for UroGen Pharma?
- What is UroGen Pharma annual EBITDA year-on-year change?
- What is UroGen Pharma quarterly EBITDA?
- What is the all time high quarterly EBITDA for UroGen Pharma?
- What is UroGen Pharma quarterly EBITDA year-on-year change?
- What is UroGen Pharma TTM EBITDA?
- What is the all time high TTM EBITDA for UroGen Pharma?
- What is UroGen Pharma TTM EBITDA year-on-year change?
What is UroGen Pharma annual EBITDA?
The current annual EBITDA of URGN is -$110.33M
What is the all time high annual EBITDA for UroGen Pharma?
UroGen Pharma all-time high annual EBITDA is $1.01M
What is UroGen Pharma annual EBITDA year-on-year change?
Over the past year, URGN annual EBITDA has changed by -$28.43M (-34.71%)
What is UroGen Pharma quarterly EBITDA?
The current quarterly EBITDA of URGN is -$38.89M
What is the all time high quarterly EBITDA for UroGen Pharma?
UroGen Pharma all-time high quarterly EBITDA is $13.98M
What is UroGen Pharma quarterly EBITDA year-on-year change?
Over the past year, URGN quarterly EBITDA has changed by -$9.45M (-32.11%)
What is UroGen Pharma TTM EBITDA?
The current TTM EBITDA of URGN is -$119.79M
What is the all time high TTM EBITDA for UroGen Pharma?
UroGen Pharma all-time high TTM EBITDA is $4.57M
What is UroGen Pharma TTM EBITDA year-on-year change?
Over the past year, URGN TTM EBITDA has changed by -$34.65M (-40.70%)